TIDMETX
RNS Number : 6594M
e-Therapeutics plc
01 May 2018
e-Therapeutics PLC (ETX.L) announces collaboration with C4X
Discovery Holdings PLC (C4X.L) to discover novel strategies for the
treatment of Parkinson's disease
Leverages e-therapeutics' network-driven drug discovery (NDD)
capabilities with C4XD's genomics technology to identify new
cellular mechanisms that are important in the pathology of this
debilitating disease
Oxford, May 1, 2018 - e-therapeutics plc (AIM: ETX,
"e-therapeutics" or the "Company"), the network-driven
computational drug discovery company, today announces that it has
entered into a collaboration agreement with C4X Discovery Holdings
PLC (C4X.L) ("C4XD") to combine its drug discovery platform with
the latter's genomics capabilities. The collaboration will aim to
identify novel intervention strategies that have potential in the
treatment of Parkinson's disease ("PD"), a debilitating and
progressive neurological disease where there remains a significant
unmet medical need.
The collaboration is based on leveraging the power of
e-therapeutics' proprietary Network-Driven Drug Discovery (NDD)
platform with C4XD's Taxonomy3 technology, C4XD's innovative
DNA-based target identification platform that utilises human
genetic datasets to identify novel patient-specific targets.
Taxonomy3 has already identified 180 novel disease-associated
genes for PD. Using these results, e-therapeutics will apply its
pioneering NDD platform to derive new insights into the
corresponding cellular mechanisms in order to understand their
interplay and centrality in the pathology of the disease. It is
hoped that this work will ultimately lead to the identification of
new treatment strategies, molecular targets and ultimately, novel
drugs.
There is currently no cure for Parkinson's disease, which is
estimated to affect c.10 million people worldwide(1) .
Results generated in the collaboration shall be jointly owned by
e-therapeutics and C4XD. The financial terms of the agreement are
undisclosed.
Ray Barlow, CEO of e-therapeutics, said: "We are delighted to be
entering into this collaboration with C4XD, which has the ultimate
ambition of discovering novel drugs for Parkinson's Disease, a
debilitating and progressive condition where there remains a
significant unmet medical need for truly effective treatments. In
addition to validating our Network-Driven Drug Discovery (NDD)
approach in multiple, diverse areas of biology, we have also been
working on genome-based functionality of our NDD platform, in a
number of areas including triple negative breast cancer.
Our NDD platform is a unique approach that interrogates complex
biology in a fundamentally different way. Our aim is to use the
genomic associations that C4XD's Taxonomy3 technology platform has
uncovered, to create new therapeutic approaches to treat this
devastating disease.
There is potentially an exciting technological synergy between
our approaches and we are looking forward to combining our
expertise and working together."
(1) European Parkinson's Disease Association.
For more information, please contact:
e-therapeutics plc Tel: +44 (0)1993 883 125
Ray Barlow, Chief Executive Officer www.etherapeutics.co.uk
Steve Medlicott, Finance Director
Numis Securities Limited Tel: +44 (0) 207 260 1000
Michael Meade / Freddie Barnfield www.numis.com
(Nominated Adviser)
James Black (Corporate Broking)
FTI Consulting Tel: +44 (0) 203 727 1000
Simon Conway/Brett Pollard etherapeutics@fticonsulting.com
About e-Therapeutics
We are an Oxford, UK-based company with a unique and powerful
computer-based drug discovery platform and a specialised approach
to network biology.
Our novel network-driven methodology allows us to discover new
and better drugs in a more efficient and effective way.
We use our highly productive drug Discovery Engine to develop
our own IP-protected, preclinical drug discovery programmes which
will be of interest to partners looking to acquire or in-license
novel and differentiated assets. We are currently developing two
programmes in immuno-oncology and have a number of partner-ready
projects in areas such as fibrosis and tumour microenvironment.
Because of our novel network-driven drug (NDD) discovery
approach, we believe there is potential to enter into several
different types of collaborative partnerships with biotech, pharma
and other technology companies to create sustainable mutual
value.
About Network-Driven Drug Discovery (NDD)
e-Therapeutics' proprietary NDD platform comprises a suite of
powerful computational tools to augment and interrogate the vast
amount of biological information currently available in both public
and private databases.
Our NDD platform is founded on sophisticated network science and
employs techniques such as machine learning, artificial
intelligence and state-of-the-art data analysis tools. Using our
biological expertise, we can create and analyse network models of
disease to identify likely proteins that could effectively be
disrupted to treat the disease.
We believe that our network-driven approach more realistically
reflects the true complexity of disease, with its multiple and
often interconnected cellular pathways. By modelling and analysing
disease networks and considering the pattern of connections between
proteins, and not just single pathways, we more efficiently select
the very best drug-like compounds for screening and for subsequent
medicinal chemistry and pre-clinical testing. With our novel
methodology, significant numbers of active molecules can be
identified and tested quickly. Our approach is highly productive
and consistently generates hits that have been progressed into
potent, selective and novel drug molecules.
Our overall aim is to discover more efficacious drugs more
effectively. By using more biologically realistic, cell and
tissue-based assays we can choose and design compounds that are
more likely to translate into better, more clinically efficacious
drugs.
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline in
inflammation, neurodegeneration, immuno-oncology, addiction, and
diabetes with a number of new drug candidates identified and
further progress made towards the pre-clinical licensing
discussions. In selecting new targets C4X Discovery will focus on
the high-value disease areas and will continue to maximise value
from opportunistic areas, for example, immuno-oncology, addiction,
and diabetes.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLLFVASSIIVIT
(END) Dow Jones Newswires
May 01, 2018 02:00 ET (06:00 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024